Challenges persist despite promising advance In January 2025, the National Institute for Health and Care Excellence (NICE) approved the use of the gene editing therapy exagamglogene autotemcel ...

NEWS 19 May 2025 Correction 19 May 2025 World first: ultra-powerful CRISPR treatment trialled in a person Immune-cell function improved in a teenager whose DNA was altered using prime editing.

Targeting immune cells with CRISPR/Cas9 In this study, researchers used CRISPR/Cas9 technology to modify a type of immune cell known as tumor-infiltrating lymphocytes (TILs). Specifically, they ...

All other approved CAR T-cell therapies target B cell cancers, which do not have this T cell self-targeting complication. After using CRISPR gene editing to modify the CAR T cells to prevent these ...

They will harvest a type of immune cell, known as T cells, from a patient's blood and then use CRISPR to tinker with a particular gene in a way that will activate the T cells to attack cancer ...

The Phase 1 clinical trial of VCTX210 will assess its safety, tolerability, and immune evasion in patients with T1D. This program is being advanced by CRISPR Therapeutics and ViaCyte as part of a ...

The Phase 1 clinical trial of VCTX210 is designed to assess its safety, tolerability, and immune evasion in patients with T1D. This program is being advanced by CRISPR Therapeutics and ViaCyte as ...

Photo by Toondelamour / Getty Images A new gene therapy, utilizing the gene-editing tool known as CRISPR to treat sickle-cell disease, has received approval in the U.K., the U.S., and the EU.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR ...

Researchers found that, upon CAR T-cell therapy, microglia – the brain’s immune cells – produces chemicals like cytokines and chemokines as part of its inflammatory response.